AstraZeneca: ZORA Real-World Evidence Demonstrates That LOKELMA Substantially Increases Cardiorenal Patients' Chances of Maintaining Lifesaving RAASi Therapy
November 03, 2023
November 03, 2023
WILMINGTON, Delaware, Nov. 3 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release on Nov. 2, 2023:
Results from the real-world ZORA observational multi-country study presented today at the American Society of Nephrology (ASN) 2023 shows that treating hyperkalemia (HK) with the potassium binder LOKELMA (sodium zirconium cyclosilicate) can allow patients with chronic kidney disease (CKD) or heart failure (HF) to maintain their lifesaving renin-angiot . . .
Results from the real-world ZORA observational multi-country study presented today at the American Society of Nephrology (ASN) 2023 shows that treating hyperkalemia (HK) with the potassium binder LOKELMA (sodium zirconium cyclosilicate) can allow patients with chronic kidney disease (CKD) or heart failure (HF) to maintain their lifesaving renin-angiot . . .